Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2013 | short review | Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013

ASH 2012 update chronic lymphocytic leukemia—the best is yet to come

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2013
Autoren:
Lukas Weiss, Thomas Melchardt, Richard Greil, Georg Hopfinger

Abstract

Treatment of CLL has been significantly improved through combination of chemotherapy and rituximab. Furthermore, the positive influence of MRD negativity on survival was clearly demonstrated. More recently, drugs with novel modes of action, e.g. targeting B-cell receptor or downstream, chemotherapy-free therapy concepts seem to possible in the near future. More importantly, administration of new drugs with the aim to overcome unfavorable prognostic factors as 17p- or BIRC3, NOTCH1 and SF3B1 is warranted.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe